{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-26-000023","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.091504+00:00","generated_at":"2026-05-16T02:58:47.092370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agios Q4 net loss $108M; AQVESME approved for thalassemia, U.S. launch started","bullets":["PYRUKYND worldwide net revenue $20M in Q4 ($16M U.S., $4M ex-U.S.), up 49% YoY in U.S.","Full-year 2025 PYRUKYND revenue $54M; net loss $108M in Q4 vs $96.5M in Q4 2024.","FDA approved AQVESME (mitapivat) for thalassemia in Dec 2025; U.S. launch began late Jan 2026.","Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026.","Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline data in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-26-000023","json":"https://secwatch.observer/filing/0001439222-26-000023.json","markdown":"https://secwatch.observer/filing/0001439222-26-000023.md","text":"https://secwatch.observer/filing/0001439222-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/0001439222-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000023/agio-20260212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:58:47.092370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}